[Leading symptom of anxiety and tension and its concomitant somatic manifestations. A multicenter trial of fluspirilene versus bromazepam].
A group of 82 nonselected patients with the leading symptom "anxiety" as part of psychoreactive disturbances was included in a study comparing the effectiveness of fluspirilene and bromazepam. The results of an earlier pilot study showing on the whole the superiority of fluspirilene versus bromazepam was confirmed. The absence of significant side-effects under either medication seems to indicate, that the administration of the low-dose long-acting neuroleptic might be a preferable alternative to tranquilizers, especially in patients, in whom a danger of misuse cannot be excluded.
D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy* / Q000523:psychology; D001960:Bromazepam / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D005484:Fluspirilene / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013001:Somatoform Disorders / Q000188:drug therapy* / Q000523:psychology; D013141:Spiro Compounds / Q000627:therapeutic use*; D013315:Stress, Psychological / Q000188:drug therapy* / Q000523:psychology
D014151:Anti-Anxiety Agents; D013141:Spiro Compounds; D005484:Fluspirilene; D001960:Bromazepam
Leitsymptom Angst und Spannung und dessen somatische Begleiterscheinungen. Multizentrische Prüfung Fluspirilen versus Bromazepam.